Registro sencillo

dc.rights.licenseAttribution 4.0 International*
dc.contributor.authorAyala, Unai
dc.contributor.otherdel Pino, Rocío
dc.contributor.otherMurueta Goyena, Ane
dc.contributor.otherAcera, Marian
dc.contributor.otherFernández, Mónica
dc.contributor.otherTijero, Beatriz
dc.contributor.otherCarmona, Mar
dc.contributor.otherFernández, Tamara
dc.contributor.otherGabilondo, Iñigo
dc.contributor.otherGómez Esteban, Juan Carlos
dc.date.accessioned2022-02-15T14:34:00Z
dc.date.available2022-02-15T14:34:00Z
dc.date.issued2021
dc.identifier.issn1932-6203en
dc.identifier.otherhttps://katalogoa.mondragon.edu/janium-bin/janium_login_opac.pl?find&ficha_no=166827en
dc.identifier.urihttps://hdl.handle.net/20.500.11984/5463
dc.description.abstractObjective To prospectively evaluate nocturnal sleep problems and excessive daytime sleepiness (EDS) in Parkinson’s disease (PD) patients, and analyze the influence of motor symptoms, treatment, and sex differences on sleep problems in PD. Methods Sleep disturbances of 103 PD patients were assessed with Parkinson’s Disease Sleep Scale (PDSS) and the Epworth Sleepiness Scale (ESS). Student’s t-test for related samples, one-way ANOVA with Tukey’s HSD post hoc test were used to assess group differences. Bivariate correlations and mixed-effects linear regression models were used to analyze the association between clinical aspects and sleep disturbances over time. Results At baseline, 48.5% of PD patients presented nocturnal problems and 40% of patients presented EDS. The PDSS and ESS total score slightly improve over time. Nocturnal problems were associated with age and motor impartment, explaining the 51% of the variance of the PDSS model. Males presented less nocturnal disturbances and more EDS than females. Higher motor impairment and combined treatment (L-dopa and agonist) were related to more EDS, while disease duration and L-dopa in monotherapy were related to lower scores, explaining the 59% of the model. Conclusions Sleep disturbances changed over time and age, diseases duration, motor impairment, treatment and sex were associated with nocturnal sleep problems and EDS. Agonist treatment alone or in combination with L-dopa might predict worse daytime sleepiness, while L-dopa in monotherapy is related to lower EDS, which significantly affects the quality of life of PD patients.en
dc.language.isoengen
dc.publisherPLOSen
dc.rights© 2021 Del Pino et al.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleClinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson's diseaseen
dcterms.accessRightshttp://purl.org/coar/access_right/c_abf2en
dcterms.sourcePLoS ONEen
local.contributor.groupTeoría de la señal y comunicacioneses
local.description.peerreviewedtrueen
local.identifier.doihttps://doi.org/10.1371/journal.pone.0259935en
local.contributor.otherinstitutionhttps://ror.org/0061s4v88es
local.contributor.otherinstitutionUPV/EHUes
local.contributor.otherinstitutionhttps://ror.org/03nzegx43es
local.contributor.otherinstitutionhttps://ror.org/01cc3fy72es
local.source.detailsVol. 16. N. 12. N. artículo e0259935, 2021en
oaire.format.mimetypeapplication/pdf
oaire.file$DSPACE\assetstore
oaire.resourceTypehttp://purl.org/coar/resource_type/c_6501en
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85en


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(es)

Registro sencillo

Attribution 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International